Management of rare types Mycosis fungoides and Sézary syndrome

Management of rare types of Mycosis fungoides and Sézary syndrome

Mycosis Fungoides and Sézary Syndrome

Mycosis fungoides and Sézary syndrome are rare types of CTCL. Sézary syndrome is more aggressive, with widespread skin redness (erythroderma), blood, and lymph nodes, whereas mycosis fungoides develops gradually with patchy rashes. There is no cure, but therapies can help manage symptoms and delay progression.

Mycosis Fungoides

• Type: Non-Hodgkin lymphoma affecting cutaneous T cells.
• It has a slow onset and is commonly misinterpreted as eczema or psoriasis.

Symptoms:

• Early symptoms include scaly patches and  itchy rash on sun-protected areas (buttocks, thighs, and breasts).
• Later, plaques, tumours, hair loss, and swollen lymph nodes may develop.
• Progression: Skin-confined for years; may spread to lymph nodes, blood, or organs.

Treatment:

• Steroid creams, topical chemotherapy with mechlorethamine, and phototherapy (PUVA, UVB) are all options for skin treatment.
• Interferon, HDAC inhibitors, monoclonal antibodies, and retinoids (bexarotene) are systemic.
• Localised or complete skin radiation.
• Advanced bone marrow transplant.
• Prognosis: Early stages have a 95% 10-year survival probability, while advanced disease reduces life expectancy to 3-5 years.

Sézary Syndrome

• Leukemic CTCL affects skin, blood, and lymph nodes.
• Rapid, systemic engagement.

Symptoms:

• Rash with severe itching, burning, and discomfort.
• Swollen lymph nodes, hair loss, nail changes, and ectropion.
• Fever, fatigue, and weight loss.

Diagnosis:

• Blood smear displaying Sézary cells (malignant T cells with folded “brain-like” nuclei).
• CT/PET imaging, skin and lymph node biopsy, and flow cytometry were performed.

Treatment:

The video is about the Treatment of the early stages of disease

• Skin-directed treatments include topical steroids, retinoids, phototherapy, and whole skin electron beam therapy.
• Systemic: ECP, targeted therapy, immunotherapy, HDAC inhibitors, and chemotherapy.
• Allogeneic bone marrow transplant in advanced instances.
• Prognosis: Chronic, incurable; ~24% 5-year survival rate.

 Mycosis fungoides causes and  Sézary syndrome

• Causes of Mycosis Fungoides include DNA abnormalities in T-cells, which impede normal cell death and cause uncontrolled proliferation.
• Despite its name, it is not fungal.

Risk factors:

• More common in 50+ adults
• Men are more likely
• Blacks are at higher risk, typically younger.

Possible causes:

• Environmental toxins (e.g., industrial chemicals, fire retardants)
• Long-term immune stimulation (autoimmune illness)
• Studying viral illnesses, no definitive link yet
• Genetics: Mutations are normally acquired, not inherited.

Sézary Syndrome Causes

• T-cell genetic mutations: Similar to MF, but cancerous cells called “Sézary cells” circulate in blood.
• Leukemic variant: Systemic CTCL affecting skin, blood, and lymph nodes.

Risk factors:

• Elderly (usually diagnosed in 60s–70s)
• Mycosis fungoides history (MF can become SS)
• HTLV‑1/II virus infection may be linked in certain places (Japan, the Caribbean, and the Middle East).

Pathophysiology:

• Malignant CD4+ T-cells have aberrant markers (CD7, CD26 deletion).
• Cytokines from these cells weaken immunity, increasing infection risk.

Who's vulnerable?

Though the cause is unknown, mycosis fungoides and Sézary syndrome patients share demographic and clinical traits. Risk patterns have been found for some uncommon malignancies.

General CTCL Risks

• Cases mostly affect adults over 50.
• Men are impacted twice as often as women.
• Ethnicity: Blacks are more likely to be diagnosed early and with advanced disease.
• Immunological system dysfunction: Autoimmune or chronic immunological activation may raise risk.
• Exposure to industrial chemicals, insecticides, or fire retardants may be a factor (under study).
• Some cases have been connected to HTLV-1/II infection, particularly in endemic countries like Japan, the Caribbean, and the Middle East.

Specific Mycosis Fungoides Risks

• Slow onset: Misdiagnosed as eczema or psoriasis early on.
• Risk: Older men, especially darker-skinned ones, are more likely to develop MF.
• A small percentage of MF patients develop progressive disease or Sézary syndrome.

Specific Sézary Syndrome Risks

• Age: Usually diagnosed in the 60s–70s.
• Patients with long-term MF may acquire SS as a leukemic change.
• Systemic involvement: Immune suppression makes SS more aggressive and infectious.

Comparative Table Feature: Mycosis Fungoides Sézary Syndrome

• Slow, skin-specific onset. Systemic, fast
• Pimples, plaques, tumours. Scaling, diffuse erythroderma
• In late-stage disease, blood involvement occurs, and early Sézary cells appear.
• Prognosis: Early good, poor, aggressive
• Treatment focus: Skin-directed and systemic. Systemic + skin-directed

Key Risks

• Both disorders weaken the immune system, increasing infection risk.
• Sézary syndrome can become aggressive lymphoma.
• Emotional and quality-of-life impacts from continuous itching, noticeable skin changes, and long-term treatment.

Recent cutaneous T cell lymphoma therapy

New CTCL treatments for mycosis fungoides and Sézary syndrome include mogamulizumab, lacutamab, CAR-T therapies, and new skin-directed techniques including HyBryte photodynamic therapy. These breakthroughs improve response rates and quality of life, especially for relapsed or refractory individuals.

Important New Therapies

• Anti-CCR4 monoclonal antibody Mogamulizumab plays a significant role in inflammation and autoimmune diseases and is often overexpressed in specific T-cells.
• Improves symptoms and survival in patients with relapsed/refractory mycosis fungoides and Sézary syndrome.
• Data from the 2026 World Congress of Cutaneous Lymphomas demonstrate real-world efficacy and patient-reported results.

Lacutamab is an anti-KIR3DL2 antibody.

• The FDA granted breakthrough treatment status for Sézary syndrome in 2025.
• Results: ~43% response rate, median length of 25.6 months.

CAR-T Therapy

• CTX130, a CD70-directed allogeneic CAR-T, resolved T-cell fratricide concerns.
• It met a response rate of ~46% in strongly pretreated individuals.
• Combine HDAC and PI3K inhibitors
• Combine tenalisib, duvelisib, and linperlisib with HDAC inhibitors.
• Refractory CTCL response rates 50–60%.

HYBRYTE Photodynamic Therapy

• Light-activated synthetic hypericin.
• The Phase 3 FLASH trial helped with early-stage disease.

Risks and Factors

• Possible side effects include skin irritation (phototherapy), immunological suppression (CAR-T, antibodies), and GI toxicity (HDAC/PI3K combinations).
• Access: Many medicines are in clinical trials; availability varies by region.
• Quality of life: Toxicology might reduce survival benefits, therefore patient-reported outcomes are increasingly included in approvals.

CTCL diagnostics

The diagnosis of cutaneous T-cell lymphoma (CTCL) involves skin samples, blood testing, and sophisticated imaging techniques. CTCL commonly mimics eczema or psoriasis, requiring numerous biopsies and specialist molecular tests to diagnose.

Essential Diagnostics

• Physical checkup
• A dermatologist checks for scaly patches, plaques, and malignancies.
• Assesses lymph node swelling and systemic involvement.

Biopsy of skin

• Circular punch or scalpel biopsy.
• A pathologist checks tissue for cancerous T-cells.
• Since early lesions resemble benign rashes, many biopsies may be needed.

Tests of blood

• All-blood CBC with differential.
• Buffy coat smear for Sézary cells (malignant T-cells with folded nucleus).
• Assess disease aggressiveness with LDH and uric acid.

Cytometry flow

• Identifies aberrant T-cells (e.g., CD4/CD8 ratio >10).
• Detects T-cell antigen loss (CD2, CD3, CD4, CD5).
• Verifies pathogenic clones.

Molecular tests

• Use PCR or Southern blot to identify a dominant T-cell clone.
• Differentiates CTCL from inflammatory dermatoses.

Genetic testing

• Identifies DNA alterations causing T-cell proliferation issues.

Imaging tests

• CT or PET scans for lymph node or organ spread.
• X-ray of the chest for lung involvement.

Diagnostic Criteria for Sézary Syndrome

• ≥1000/µL absolute Sézary cell count.
• The immune system is abnormal, with an increased CD4+ population and a changed CD4/CD8 ratio.
• There is evidence of a cancerous T-cell clone in the peripheral blood.

Risks and Challenges

• Possible misdiagnosis: Early CTCL lesions resemble eczema/psoriasis.
• Need for repeat biopsies: Initial samples may not include cancer cells.
• Systemic involvement: Needs imaging and blood tests to prevent understaging.

Conclusion

Cutaneous T-cell lymphomas (CTCL), also known as mycosis fungoides and Sézary syndrome, are rare but serious blood cancers that affect the skin.

Early skin-directed therapy helps manage slow-growing mycosis fungoides, which can remain on the skin for years.

Sézary syndrome is an aggressive leukemia that affects the blood and lymph nodes early and has inferior survival.

CTCL is a difficult disease that requires multidisciplinary diagnosis and tailored treatment. Research is improving patient survival and quality of life.